Today, Salvo Health announced a $8.5M Series A funding round led by ManchesterStory, City Light Capital, and Threshold Ventures, with participation from new investors including The Artemis Fund, Contour Venture Partners, and others.
Salvo Health is emerging as the leader in helping gastrointestinal (GI) providers across the U.S. adopt a hybrid, AI-enhanced care model, offering brick & mortar clinics an easy-to-implement continuous care platform that saves time, increases revenue, and improves patient outcomes.
Read More – Superstate Raises $82.5M in Series B Funding
Salvo ended 2025 having grown patients and revenue by 800% YoY, and enterprise agreements with GI doctors by more than 1,000%.
Salvo has signed agreements with 801 GIs, representing 16% of all independent GIs in the U.S., to deploy wraparound care for their clinic patients. Enterprise customers include three of the four largest GI practices in the country, together seeing over 1.1 million GI patients a year across ten states.
Other new equity investors with this Series A funding include Owl Capital and Impact X Capital Partners. Both were previously investors from Salvo’s separate $4.7M Convertible Note raised in 2025. In addition, existing investors Human Ventures, Torch Capital, Felicis Ventures, and Alumni Ventures all participated in the latest round.
Read More – Baseten Raises $300M in Funding
